Sapropterin Dihydrochloride (Kuvan)
Tetrahydrobiopterin (BH4) analog for phenylketonuria
Sapropterin Dihydrochloride (Kuvan)
Forms and strengths
Form: TabletStrength: 100 mg tablets; 100 mg and 500 mg sachets (powder for oral solution)
References
Indication
- Sapropterin dihydrochloride is used, together with a phenylalanine-restricted diet, to lower blood phenylalanine levels in patients with hyperphenylalaninemia due to BH4-responsive phenylketonuria (PKU).
- Not all patients with PKU respond to sapropterin; a therapeutic trial period is needed to determine whether an individual patient responds.
Pregnancy
- There are no adequate, well-controlled studies of sapropterin in pregnant women, though available pregnancy registry data have not shown an increased risk of major birth defects.
- Poorly controlled blood phenylalanine levels during pregnancy in women with PKU are themselves teratogenic and can cause serious birth defects, known as maternal PKU syndrome.
- Strict dietary control of phenylalanine before and during pregnancy is the first-choice treatment; sapropterin should be used only if diet alone does not adequately control blood phenylalanine.
- Sapropterin has not been studied for use during labour and delivery and is not recommended for this purpose.
Breastfeeding
- It is not known whether sapropterin passes into human breast milk.
- Because of the potential for serious reactions in a nursing infant, and evidence of tumour development in an animal carcinogenicity study, sapropterin should not be used while breastfeeding.
Geriatrics
- Clinical studies of sapropterin did not include patients aged 50 years and older.
- It is not known whether older patients respond differently than younger patients.
Pediatrics
- Sapropterin is authorized for use in patients 1 month of age and older with PKU.
- Safety and efficacy have not been established in infants younger than 1 month.
- Children younger than 7 years, including infants, have a higher risk of developing low blood phenylalanine levels during treatment and need closer monitoring.
- Prolonged low blood phenylalanine and tyrosine levels during infancy have been linked to impaired neurodevelopment.
Dosage & Administration
- The recommended starting dose of sapropterin is 10 mg/kg taken once daily.
- Blood phenylalanine levels are checked after the first week and periodically over the first month to determine response.
- If blood phenylalanine has not decreased after a month at the starting dose, the dose may be increased weekly up to a maximum of 20 mg/kg/day.
- Patients whose blood phenylalanine does not improve after a month at the maximum dose are considered non-responders and treatment should be stopped.
- Once a response is confirmed, the dose is adjusted within a range of 5 to 20 mg/kg/day based on ongoing blood phenylalanine monitoring.
- Tablets can be swallowed whole or dissolved in water or apple juice; the powder for oral solution is dissolved in water or apple juice; both should be consumed within 15 minutes of preparation.
- Sapropterin should be taken with a meal, since food increases how much of the drug is absorbed.
- A missed dose should be taken as soon as possible, but two doses should not be taken on the same day.
- No dedicated dosing studies exist for patients with kidney or liver impairment; such patients should be monitored carefully during treatment.
Overdose
If overdose is suspected, seek emergency medical attention immediately or contact your regional Poison Control Centre without delay.
- Reported overdoses of sapropterin have caused mild, temporary headache and dizziness that resolved without treatment.
- One reported pediatric overdose caused hyperactivity that resolved once the dose was reduced back to the recommended level.
- Upper abdominal pain has been reported after doses above the recommended maximum.
- A single supratherapeutic dose in a study caused a dose-related shortening of the QT interval on ECG, along with abdominal pain and dizziness in some subjects.
- Overdose should be treated based on the specific symptoms present.
Common side effects
- Headache may occur.
- Diarrhea may occur.
- Abdominal pain may occur.
- Upper respiratory tract infection may occur.
- Throat pain may occur.
- Vomiting may occur.
- Nausea may occur.
- Low blood phenylalanine levels (hypophenylalaninemia) may occur, especially in young children.
Serious side effects
Serious side effects require immediate discussion with the prescriber or emergency care.
- Gastritis and esophagitis have been reported and, if untreated, can lead to complications such as ulcers, strictures, or bleeding.
- Hypersensitivity reactions, including anaphylaxis, have occurred; signs include wheezing, difficulty breathing, coughing, low blood pressure, flushing, nausea, and rash.
- Seizures and worsening of existing seizure disorders have been reported.
- Hyperactivity has been reported, particularly with doses above the recommended maximum.
- Prolonged low blood phenylalanine in young children may affect neurological development.
- Seek urgent medical attention for signs of a severe allergic reaction, chest or throat tightness, difficulty breathing, or a new or worsening seizure.
Use with caution
- Use with caution in patients taking medicines that cause blood vessel widening, such as nitrates or PDE-5 inhibitors (e.g., sildenafil), since the combination may lower blood pressure further.
- Use with caution in patients taking medicines that affect folate metabolism, such as methotrexate or trimethoprim, since these can reduce sapropterin's effectiveness.
- Use with caution in patients taking levodopa, since seizures, agitation, or irritability have been reported with concurrent use.
- Use with caution in patients with liver impairment, since this population has not been studied and liver damage can affect phenylalanine metabolism.
- Use with caution in patients with kidney impairment, since this population has not been studied.
- Use with caution in patients with a history of seizures, since exacerbation of seizures has been reported.
- Use with caution in young children, who are at higher risk for low blood phenylalanine levels requiring frequent monitoring.
Contraindications
- Contraindicated in patients with known hypersensitivity to sapropterin dihydrochloride or to any ingredient in the tablet, powder, or container.
Drug interactions
- Medicines that cause vasodilation, including nitrates, sildenafil, vardenafil, tadalafil, and minoxidil, may have an additive blood-pressure-lowering effect when combined with sapropterin.
- Methotrexate, trimethoprim, and other drugs that affect folate metabolism may reduce sapropterin's effectiveness by lowering BH4 levels.
- Levodopa combined with sapropterin has been associated with seizures, worsened seizures, over-stimulation, or irritability in patients with underlying neurologic conditions.
- Sapropterin may increase blood levels of drugs that are substrates of the BCRP transporter, such as rosuvastatin.
- A single therapeutic dose of sapropterin did not affect the pharmacokinetics of digoxin in a clinical study.
Food interactions
- Sapropterin should be taken with a meal, since a high-fat, high-calorie meal increases its absorption substantially; taking it on an empty stomach can reduce how well it works.
Time of administration
- Sapropterin is taken once daily with a meal, ideally at about the same time each day, to help maintain consistent absorption.
Storage
- Store sapropterin tablets at room temperature (20-25°C, with excursions permitted between 15-30°C) and protect them from moisture.
- Store the powder for oral solution at room temperature (15-30°C) and protect it from moisture.
Patient take-away
- Sapropterin, combined with a phenylalanine-restricted diet, helps lower blood phenylalanine levels in people with BH4-responsive PKU, but it does not replace dietary management.
- Take sapropterin with a meal every day and keep up with your prescribed low-phenylalanine diet.
- Regular blood tests are needed to check your phenylalanine levels and adjust your dose or diet as needed.
- Contact your healthcare provider promptly if you notice stomach pain, signs of an allergic reaction, or a new seizure.